<- Go Home
Greenbrook TMS Inc.
Greenbrook TMS Inc., together with its subsidiaries, controls and operates a network of outpatient mental health services centers in the United States. Its centers specialize in the provision of transcranial magnetic stimulation (TMS) therapy, an FDA-cleared neurostimulation therapy for the treatment of major depressive disorder and other mental health disorders. The company also offers Spravato, an esketamine nasal spray; and other treatment modalities for the treatment of depression and related psychiatric services. Greenbrook TMS Inc. was founded in 2011 and is headquartered in Toronto, Canada.
Market Cap
$3.2M
Volume
893.6K
Cash and Equivalents
$3.3M
EBITDA
-$30.3M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$1.3M
Profit Margin
1.70%
52 Week High
$0.64
52 Week Low
$0.01
Dividend
N/A
Price / Book Value
-0.01
Price / Earnings
-0.02
Price / Tangible Book Value
-0.01
Enterprise Value
$161.0M
Enterprise Value / EBITDA
-5.32
Operating Income
-$31.8M
Return on Equity
60.92%
Return on Assets
-27.89
Cash and Short Term Investments
$3.3M
Debt
$165.0M
Equity
-$127.6M
Revenue
$75.2M
Unlevered FCF
-$21.0M
Sector
Health Care Providers and Services
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium